Komori
COSMOS Pharmaceutical (3349) · InitiativeUpdate to full-year adoption impact

Application of the Accounting Standard for Revenue Recognition for the Fiscal Year Ending May 2022

First written in FY2020. 1 of 6 entries say "Advanced", first in FY2021. Latest entry: FY2022.

6entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2021 – FY2022-Q1OtherFY2022-Q2 – FY20222020: 120202021: 220212022: 32022
Same theme, other companies
Impact of Applying Revenue Recognition Accounting Standards on Financial StatementsA theme 365 companies write about · 218 as a headwind · 11 as a tailwind

82 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 365 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022Update to full-year adoption impactAnnual report

    「As a result, revenue for the fiscal year decreased by ¥12,705 million, cost of sales decreased by ¥11,339 million, and selling, general and administrative expenses decreased by ¥1,365 million, but there was no impact on operating profit, ordinary profit or profit before income taxes and other adjustments for the year.」

    The Accounting Standard for Revenue Recognition and related standards were adopted from the beginning of the fiscal year, reducing reported revenue and other amounts, but the company stated that there was no impact on operating profit, ordinary profit or profit before income taxes and other adjustments for the year.
  2. FY2022-Q3Updated Impact of ApplicationAnnual report

    「As a result, revenue for the nine months ended 28 February decreased by ¥9,627 million, cost of sales decreased by ¥8,594 million, and selling, general and administrative expenses decreased by ¥1,032 million, but there was no impact on operating profit, ordinary profit or profit before income taxes and other adjustments for the year.」

    The company stated that, following adoption of the Accounting Standard for Revenue Recognition, revenue for the nine months ended 28 February decreased by ¥9,627 million, cost of sales by ¥8,594 million, and selling, general and administrative expenses by ¥1,032 million, but there was no impact on operating profit or other items.
  3. FY2022-Q2Updated Impact of ApplicationAnnual report

    「As a result, revenue for the six months ended 30 November decreased by ¥6,441 million, cost of sales decreased by ¥5,794 million, and selling, general and administrative expenses decreased by ¥646 million, but there was no impact on operating profit, ordinary profit or profit before income taxes and other adjustments for the quarter.」

    The company stated that, as a presentation impact of adopting the Accounting Standard for Revenue Recognition, revenue for the six months ended 30 November decreased by ¥6,441 million, but there was no impact on operating profit, ordinary profit or profit before income taxes and other adjustments for the quarter.
  4. FY2022-Q1AchievedAnnual report

    「From the beginning of the first quarter, we adopted the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020) and related standards. Revenue is recognized at the amount expected to be received in exchange for the promised goods or services when control of those goods or services transfers to the customer.」

    The Accounting Standard for Revenue Recognition and related standards were adopted from the beginning of the fiscal year ending May 2022. Revenue decreased by ¥3,142 million, but there was no impact on operating profit, ordinary profit or profit before income taxes and other adjustments for the quarter.
  5. FY2021AdvancedAnnual report

    「The cumulative impact will be reflected in net assets at the beginning of the next consolidated fiscal year as a result of adopting the Accounting Standard for Revenue Recognition and related standards, but the impact on the opening balance of retained earnings will be immaterial.」

    The company maintained its plan to adopt the standards from the beginning of the fiscal year ending May 2022 and assessed the impact on the opening balance of retained earnings as immaterial.
  6. FY2020First statedAnnual report

    「Revenue Recognition Standard (Accounting Standard No. 29, 31 March 2020). (2) Scheduled adoption date: The standard is scheduled to be adopted from the beginning of the fiscal year ending May 2022.」

    The company planned to adopt the new revenue recognition standards from the beginning of the fiscal year ending May 2022 and was still evaluating the impact when the consolidated financial statements were prepared.
Moved together

"Further Growth Through Proactive Store Expansion" moved the same way as this thread, in the same document, in 2 of its 6 moves.

2222★1234
  1. ★This thread
  2. 1Further Growth Through Proactive Store Expansion2×
  3. 2Achieving a Dominant Share in Western Japan2×
  4. 3New Store Openings and Expansion of the Store Network2×
  5. 4Continued Capital Investment in New Stores2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for COSMOS Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Application of the Accounting Standard for Revenue Recognition for the Fiscal Year Ending May 2022 | COSMOS Pharmaceutical Corporation (3349) | Komori